2026 Mammary analogue secretory carcinoma indication strategy covering epidemiology, NTRK3 biology, active trials, transactions, unmet need, competition and…

2026 Desmoplastic small round cell tumor indication strategy covering epidemiology, WT1 biology, active trials, transactions, unmet need, competition and market…

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Landogrozumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Labetuzumab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Domagrozumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Carotuximab, an antibody targeting ENG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Remtolumab, an antibody targeting IL-17A × TNF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Porgaviximab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Olendalizumab, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lutikizumab, an antibody targeting IL1A × IL1B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lacnotuzumab, an antibody targeting CSF1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gedivumab, an antibody targeting Influenza A HA.